The Health Economics & Patient Value (HEPV) program is a strategic MDIC initiative focused on advancing the field of evidence generation to meet payer coverage requirements and secure patient access for all medical technologies. The goal is to speed patient access to innovative medical technologies and amplify the patient voice in selection of treatment options by:
Freespira, Inc. developed an innovative digital therapeutic treatment to address the need for accessible and effective solutions for panic disorder, panic attacks, and post-traumatic stress disorder (PTSD). As the first FDA-cleared, medication-free, at-home treatment, Freespira stands out in the crowded landscape of digital therapeutics, overcoming the limitations of traditional treatments.
About the Series
Understanding the complexities of successfully navigating the reimbursement and coverage processes to commercialize disruptive medical technologies can often be a complicated endeavor for organizations. MDIC has partnered with leading industry experts to review key components of developing a successful reimbursement strategy in a new series of informational videos. These videos highlight how to achieve commercial product success by securing favorable payer coverage, coding, and payment for new technologies.